Consequences of Real-World Surveillance of Fellow Eyes in Neovascular Age-Related Macular Degeneration

被引:4
|
作者
Onwuka, Oluchukwu [1 ,2 ]
Saddemi, Jackson L. [1 ,3 ]
Aydogmus, Fatma Sema Akkan [1 ,4 ]
Lasalle, Claudia C. [1 ,2 ]
Ramsey, David J. [1 ,2 ]
机构
[1] Lahey Hosp & Med Ctr, Beth Israel Lahey Hlth, Dept Surg, Div Ophthalmol, Burlington, MA 01805 USA
[2] Tufts Univ Sch Med, Dept Ophthalmol, Boston, MA 02111 USA
[3] Rowan Univ, Cooper Med Sch, Camden, NJ 08103 USA
[4] Ankara Sehir Hastanesi, Ophthalmol Dept, Universiteler, TR-06800 Ankara, Turkiye
来源
LIFE-BASEL | 2023年 / 13卷 / 02期
关键词
neovascular age-related macular degeneration; anti-vascular endothelial growth factor; choroidal neovascularization; optical coherence tomography; visual acuity; RANIBIZUMAB; PROGRESSION; PREDICTORS; MANAGEMENT; BLINDNESS; TIME; AMD; 1ST;
D O I
10.3390/life13020385
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
This study investigated whether the interval of monitoring at-risk, fellow eyes of patients with unilateral neovascular age-related macular degeneration (nAMD) has any bearing on the severity of the disease at the time of diagnosis. The study comprised a retrospective, cross-sectional comparative case series of treatment-naive eyes in patients who were diagnosed sequentially with nAMD. We compared the visual acuity (VA) and central macular thickness (CMT) of patients who were actively receiving intravitreal injections (IVIs) of anti-vascular endothelial growth factor (anti-VEGF) agents at the time of second eye diagnosis with the VA and CMT of patients who had ceased treatment in their first eye because of reaching end-stages of disease. Intervals of visits and frequency of monitoring the macula of fellow eyes by means of optical coherence tomography (OCT) were abstracted from the medical record. We found that the at-risk fellow eyes of patients who had stopped treatment for nAMD in their first eye prior to fellow eye conversion were monitored significantly less frequently than the fellow eyes of patients who continued to receive treatment at the time of second eye diagnosis. Despite less frequent monitoring, VA and CMT were similar at the time of fellow eye diagnosis for both groups.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Real-World Prevalence and Progress of Intraretinal and Subretinal Fluid in Eyes Switched to Faricimab for the treatment of Neovascular Age-Related Macular Degeneration
    Karamat, Ayesha Nuri
    Mauger, Stephanie
    O'Neill, Charles Patrick
    Urrea, Anna
    Corradetti, Giulia
    Chauhan, Devinder
    Samarasinghe, Gihan
    Sadda, SriniVas R.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)
  • [32] Real-World Outcomes of Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration: A Large-Scale Postmarketing Surveillance in Korea
    Ryu, Gahyung
    Noh, Donghyoun
    Moon, Guihyun
    Sagong, Min
    CLINICAL OPHTHALMOLOGY, 2021, 15 : 3601 - 3611
  • [33] High-risk characteristics of fellow eyes of patients with unilateral neovascular age-related macular degeneration
    Sandberg, MA
    Weiner, A
    Miller, S
    Gaudio, AR
    OPHTHALMOLOGY, 1998, 105 (03) : 441 - 447
  • [34] Evaluation of real-world mobility in age-related macular degeneration
    Sengupta, Sabyasachi
    Nguyen, Angeline M.
    van Landingham, Suzanne W.
    Solomon, Sharon D.
    Do, Diana V.
    Ferrucci, Luigi
    Friedman, David S.
    Ramulu, Pradeep Y.
    BMC OPHTHALMOLOGY, 2015, 15
  • [35] Evaluation of real-world mobility in age-related macular degeneration
    Sabyasachi Sengupta
    Angeline M Nguyen
    Suzanne W van Landingham
    Sharon D Solomon
    Diana V Do
    Luigi Ferrucci
    David S Friedman
    Pradeep Y Ramulu
    BMC Ophthalmology, 15
  • [36] RANIBIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN A REAL WORLD CLINICAL SETTING
    Abell, Robin
    Lim, Diane
    Kerr, Nathan
    Allen, Penelope
    Vote, Brendan
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2012, 40 : 103 - 104
  • [37] Real-world frequency and outcomes of intraocular inflammation-related adverse events in eyes with neovascular age-related macular degeneration treated with brolucizumab
    Mccoy, Jasmyne E.
    Zubricky, Ryan
    Donkor, Richard
    Miller, David G.
    Sonbolian, Nina
    Heaney, Andrew
    Bilano, Ver
    Karcher, Helene
    Coney, Joseph M.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [38] Impact of Prophylactic Ranibizumab to Prevent Neovascular Age-Related Macular Degeneration on Eyes With Intermediate Age-Related Macular Degeneration
    Chan, Clement K.
    Beaulieu, Wesley T.
    Lujan, Brandon J.
    Lalezary, Maziar
    Lent-Schochet, Daniella
    Lo, Therlinder
    Yiu, Glenn
    TRANSLATIONAL VISION SCIENCE & TECHNOLOGY, 2023, 12 (09):
  • [39] Ranibizumab in patients with neovascular age-related macular degeneration: results from the real-world LUMINOUS™ study
    Souied, E.
    Clemens, A.
    Macfadden, W.
    ACTA OPHTHALMOLOGICA, 2017, 95
  • [40] Exit Strategy for Treatment of Neovascular Age-Related Macular Degeneration in a Real-World Setting: Wishful Thinking?
    Eastline, Michael
    Said, Sadiq
    Bosch, Martina Monika
    Pascal, Knecht-Bosch
    KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2025,